KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Interest Expenses (2017 - 2025)

Arbutus Biopharma (ABUS) has disclosed Interest Expenses for 9 consecutive years, with $18000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 40.0% to $18000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $97000.0 through Dec 2025, down 29.2% year-over-year, with the annual reading at $97000.0 for FY2025, 29.2% down from the prior year.
  • Interest Expenses hit $18000.0 in Q4 2025 for Arbutus Biopharma, down from $23000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $772000.0 in Q1 2021 to a low of $18000.0 in Q4 2025.
  • Historically, Interest Expenses has averaged $263800.0 across 5 years, with a median of $108500.0 in 2023.
  • Biggest five-year swings in Interest Expenses: crashed 89.28% in 2023 and later dropped 17.65% in 2025.
  • Year by year, Interest Expenses stood at $560000.0 in 2021, then plummeted by 44.82% to $309000.0 in 2022, then plummeted by 85.76% to $44000.0 in 2023, then tumbled by 31.82% to $30000.0 in 2024, then crashed by 40.0% to $18000.0 in 2025.
  • Business Quant data shows Interest Expenses for ABUS at $18000.0 in Q4 2025, $23000.0 in Q3 2025, and $28000.0 in Q2 2025.